Functional Effects of the DAT1 Polymorphism on EEG Measures in ADHD - 29/08/11
, ELAINE SPECTER, PH.D., ANDREW SMOLEN, PH.D., CHRISTIAN HOPFER, M.D., PETER D. TEALE, M.S.E.E., MARTIN L. REITE, M.D.ABSTRACT |
Objective |
This paper examines whether dopamine transporter gene (DAT1) allele status mediates medication-related change in cognitive and neurophysiological measures among children with attention-deficiency/hyperactivity disorder (ADHD).
Method |
A single 10-mg dose of methylphenidate was given in a double-blind, placebo-controlled fashion to children with ADHD who were seen for cognitive testing and EEG recording. Buccal samples were obtained and genotyped for the DAT1 polymorphism.
Results |
DAT1 allele status was associated with performance on a sustained attention task and medication-related EEG changes. Compared with those with one or more copies of the DAT1 9-repeat allele (9R), children with two copies of the 10-repeat allele (10R) exhibited poorer performance on the vigilance task. In addition, children with 10R exhibited medication-related EEG changes of increased central and parietal β power, decreased right frontal θ power, and lower θ/β ratios; 9R carriers showed the opposite pattern.
Conclusions |
The data suggest that the DAT1 polymorphism mediates medication-related changes in cortical activity among children with ADHD.
Le texte complet de cet article est disponible en PDF.Key Words : attention-deficit/hyperactivity disorder, dopamine transporter gene, electroencephalography, methylphenidate
Plan
| Supported by the National Institutes of Child Health and Human Development ( grant CD08442-02 ), the Developmental Psychobiology Endowment Fund, and the General Clinical Research Centers Program, National Centers for Research Resources, NIH ( grant M01 RR00069 ). |
Vol 42 - N° 8
P. 986-993 - août 2003 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
